<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03694041</url>
  </required_header>
  <id_info>
    <org_study_id>OP101817.APT</org_study_id>
    <secondary_id>2017-004252-30</secondary_id>
    <nct_id>NCT03694041</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers</brief_title>
  <official_title>Double Blind, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses or Multiple Ascending Doses of APX-115 in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptabio Therapeutics, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aptabio Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety, tolerabilty, pharmacokinetics and pharmacodynamics of
      single ascending doses and multiple ascending doses of APX-115 in healthy males. This study
      also aims to evaluate the effect of food consumption on the pharmacokinetics of APX-115 and
      potential interaction between caffeine and APX-115 in healthy males.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 28, 2018</start_date>
  <completion_date type="Actual">March 6, 2019</completion_date>
  <primary_completion_date type="Actual">March 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel design for SAD and MAD studies Crossover design for Food and Drug interaction studies</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAD: incidence of treatment emergent adverse events</measure>
    <time_frame>Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: number of clinically significant abnormal findings from vital signs (blood pressure, pulse)</measure>
    <time_frame>Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: number of clinically significant abnormal findings from physical exam</measure>
    <time_frame>Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: number of clinically significant abnormal findings from electrocardiogram</measure>
    <time_frame>Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAD: number of clinically significant abnormal findings from biological tests</measure>
    <time_frame>Up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: incidence of treatment emergent adverse events</measure>
    <time_frame>Up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: number of clinically significant abnormal findings from vital signs (blood pressure, pulse)</measure>
    <time_frame>Up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: number of clinically significant abnormal findings from physical exams</measure>
    <time_frame>Up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAD: number of clinically significant abnormal findings from electrocardiogram</measure>
    <time_frame>Up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Food effect: peak serum concentration (Cmax) of APX-115 under fasting and fed conditions</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Food effect: time to reach the Cmax (Tmax) of APX-115 under fasting and fed conditions</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Food effect: area under the curve (AUC) of APX-115 under fasting and fed conditions</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Food effect: elimination rate constant (Kel) of APX-115 under fasting and fed conditions</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Food effect: ratio AUCfed/AUCfasted</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug interaction: peak serum concentration (Cmax) of a metabolic probe or APX-115</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug interaction: Time to reach the Cmax (tmax) of a metabolic probe or APX-115</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug interaction study: Area under the Curve (AUC) of a metabolic probe or APX-115</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug interaction: elimination rate constant (Kel) of a metabolic probe or APX-115</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug interaction: half-life (t1/2) of a metabolic probe or APX-115</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug interaction: volume of distribution (Vd/f) of a metabolic probe or APX-115</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug interaction: clearance of a metabolic probe or APX-115</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug interaction: Incidences of treatment emergent adverse events</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SAD: time to reach Cmax (Tmax) of APX-115</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: peak serum concentration (Cmax) of APX-115</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: lowest plasma concentration before next dosing (Ctrough)</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Area Under the Curve (AUC) of APX-115</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: volume of distribution (Vd/F) of APX-115</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: clearance (CL/F) of APX-115</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: peak serum concentration (Cmax) of APX-115</measure>
    <time_frame>Up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: time to reach the Cmax (Tmax) of APX-115</measure>
    <time_frame>Up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: Area Under the Curve (AUC) of APX-115</measure>
    <time_frame>Up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: lowest plasma concentration of APX-115 before next dosing (Ctrough)</measure>
    <time_frame>Up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: volume of distribution (Vd/F) of APX-115</measure>
    <time_frame>Up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: Clearance (CL/F) of APX-115</measure>
    <time_frame>Up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAD: accumulation ratio</measure>
    <time_frame>Up to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect &amp; drug interaction: incidence of treatment emergent adverse events</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect &amp; drug interaction: number of clinically significant findings from vital signs (blood pressure and pulse)</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect &amp; drug interaction: number of clinically significant findings from physical exam</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect &amp; drug interaction: number of clinically significant findings from electrocardiogram</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect &amp; drug interaction: number of clinically significant findings from biological tests</measure>
    <time_frame>Up to Day 4 post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Healthy</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>SAD: APX-115</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: APX-115 SAD group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Experimental: Placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD: APX-115</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: APX-115 MAD group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Experimental: Placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food effect - Fasting condition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental: APX-115 under fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food effect - fed condition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Experimental: APX-115 under fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Interaction - metabolic probe</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Experimental: metabolic probe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAD: APX-115</intervention_name>
    <description>Drug: APX-115 SAD APX-115 SAD for 1day</description>
    <arm_group_label>SAD: APX-115</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAD: Placebo</intervention_name>
    <description>Drug: Placebo Placebo for 1day</description>
    <arm_group_label>SAD: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAD: APX-115</intervention_name>
    <description>Drug: APX-115 MAD APX-115 MAD repeatedly administered.</description>
    <arm_group_label>MAD: APX-115</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAD: Placebo</intervention_name>
    <description>Matching study drug will be repeatedly administered.</description>
    <arm_group_label>MAD: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food effect: fasted and fed</intervention_name>
    <description>A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.</description>
    <arm_group_label>Food effect - Fasting condition</arm_group_label>
    <arm_group_label>Food effect - fed condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metabolic probe with or without APX-115</intervention_name>
    <description>A metabolic probe will be administered with and without APX-115.</description>
    <arm_group_label>Drug Interaction - metabolic probe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Healthy male subject, aged between 18 and 45 years inclusive

          -  Certified as healthy by a comprehensive clinical assessment

          -  Normal dietary habits

          -  Normal ECG recording on a 12-lead ECG

          -  Signing a written informed consent prior to selection

        Exclusion:

          -  Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic,
             renal, metabolic, haematological, neurologic, psychiatric, systemic, infectious or
             ocular disease

          -  Frequent headaches and / or migraine, recurrent nausea and / or vomiting

          -  Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic
             postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20
             mmHg within two minutes when changing from the supine to the standing position

          -  Blood donation (including in the frame of a clinical trial) within 2 months before
             administration

          -  General anaesthesia within 3 months before administration

          -  Presence or history of drug hypersensitivity, or allergic disease diagnosed and
             treated by a physician

          -  Inability to abstain from intensive muscular effort

          -  No possibility of contact in case of emergency

          -  Any drug intake (except paracetamol or contraception) during the last month prior to
             the first administration

          -  History or presence of drug or alcohol abuse (alcohol consumption &gt; 30 grams / day)

          -  Excessive consumption of beverages with xanthine bases (&gt; 4 cups or glasses / day)

          -  Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody,
             or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests

          -  Positive results of screening for drugs of abuse

          -  Subject who, in the judgment of the Investigator, is likely to be non-compliant or
             uncooperative during the study, or unable to cooperate because of a language problem,
             poor mental development

          -  Administrative or legal supervision
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Donazzolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eurofins Optimed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gi√®res</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

